
FDA Grants Breakthrough Status to Device for Stimulant Use Disorder
NET Recovery's wearable neurostimulation device receives FDA Breakthrough Device Designation for stimulant addiction, where no drug or device is currently approved.
Evidence-based articles, treatment guides, and the latest news in addiction recovery and mental health.

NET Recovery's wearable neurostimulation device receives FDA Breakthrough Device Designation for stimulant addiction, where no drug or device is currently approved.

OSHA released a September 24, 2026, fact sheet advising employers on stocking naloxone and training workers to reverse opioid overdoses, though it stops short of mandatory requirements.

A nationwide analysis of 1,218 opioid treatment programs finds that higher patient retention correlates with lower hospitalizations, ER visits, and mortality.

Volunteers handed out free naloxone at more than 1,000 sites in all 50 states on Sept. 24 for Save a Life Day, as federal funding rules kept drug test strips off many tables.

Urban Institute analysis: Medicaid-covered buprenorphine fills rose from 936,000 in 2010 to 8.2 million in 2025, gains now threatened by federal Medicaid cuts.

Governor Newsom signed AB 113, allocating $4.7 million for California's first state-funded research into psychedelic therapy for veterans with treatment-resistant PTSD.

A Roanoke research team wins federal funding to test whether psilocybin-assisted therapy can treat cocaine use disorder, for which no FDA-approved medication exists.

SAMHSA awards $42.3 million in block-grant supplements and $2 million to the ATTC Network to advance the 'Treatment First' model for homelessness and addiction.

Bipartisan bill from Senators Hassan and Scott would create one centralized application for federal addiction prevention, treatment and recovery grants.